Vicarious Surgical (RBOT) Director Option Grant — 8,003 Shares, $7.61
Rhea-AI Filing Summary
Vicarious Surgical director Ahmad Fuad acquired a stock option on June 27, 2025 giving the right to purchase 8,003 Class A common shares at an exercise price of $7.61. The option is reported as directly beneficially owned and has an expiration date of June 26, 2035.
The filing states the shares underlying the option will vest on June 27, 2026 (or one day prior to the issuer's next annual meeting), subject to continued service. The Form 4 was executed by an attorney-in-fact on August 11, 2025. The disclosure shows a routine director option grant with defined exercise price, vesting schedule, and expiration; no sales or dispositions are reported here.
Positive
- Director Ahmad Fuad acquired 8,003 stock options reported on 06/27/2025 with clear terms disclosed
- Vesting is specified (vesting on 06/27/2026 or one day prior to the next annual meeting), providing transparency on service conditions
- Exercise price and expiration are disclosed (exercise price $7.61, expiration 06/26/2035), clarifying potential future dilution timing
Negative
- None.
Insights
TL;DR: Director received a standard option grant for 8,003 shares at $7.61, vesting in one year — routine disclosure with limited standalone market impact.
The Form 4 documents an acquisition of a stock option by Director Ahmad Fuad on 06/27/2025 for 8,003 underlying Class A shares at a $7.61 exercise price, expiring 06/26/2035. The filing clarifies the vesting date (06/27/2026 or one day before the next annual meeting) and that ownership is direct. From a securities perspective, this is a routine officer/director compensation disclosure required under Section 16 and, by itself, does not signal a material change in company valuation or capital structure.
TL;DR: Disclosure shows a time‑based retention/compensation award to a director; documented vesting and expiration dates provide transparency but are not material alone.
The filing provides clear terms: grant date 06/27/2025, vesting by 06/27/2026 subject to continued service, exercise price $7.61, and expiration 06/26/2035. Such option grants to directors are common as alignment and retention mechanisms. The Form 4 meets Section 16 reporting requirements and offers investors transparent documentation of director compensation timing and potential dilution, though it does not disclose any immediate exercise or sale activity.